BUSINESSglobal
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug - Investor's Business Daily
Single source
Updated 3 hours ago
First seen March 20, 2026 02:56:02Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug Investor's Business Daily Lilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar WSJ Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study Bloomberg.com Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial Fierce Biotech